David Hung is back, launch­ing a new on­col­o­gy start­up with $275M and big am­bi­tions to make news in can­cer drug de­vel­op­ment

Af­ter a brief and em­bar­rass­ing side trip in­to Alzheimer’s re­search, biotech high fly­er David Hung is back, and he’s jump­ing in­to on­col­o­gy R&D once again with a brand new up­start and a whop­ping $275 mil­lion in back­ing.

Team­ing back up with some of his for­mer crew mem­bers at Medi­va­tion, which broke new ground in can­cer drug de­vel­op­ment be­fore the sale of the com­pa­ny to Pfiz­er for $14.3 bil­lion, Hung says the stealth op­er­a­tion has a pipeline with 7 pro­grams, each of which has mul­ti­ple drug can­di­dates.

Here’s the team at Nu­va­tion Bio:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER